Myriocin-mediated upregulation of hepatocyte apoA-I synthesis is associated with ERK inhibition

January 26th, 2010 by admin Leave a reply »

Sphingolipids including sphingomyelin have been implicated as potential atherogenic lipids. Studies in apolipoprotein-E (apoE) null mice have revealed that the serine palmitoyl transferase inhibitor myriocin reduces plasma levels of sphingomyelin, ceramide, sphingosine-1-phosphate and glycosphingolipids, and that this is associated with potent inhibition of atherosclerosis. Interestingly, hepatic apolipoprotein A-I (apoA-I) synthesis and plasma high density lipoprotein cholesterol levels were also increased in apoE null mice treated with myriocin. Since myriocin is a known inhibitor of ERK phosphorylation, we assessed the possibility that myriocin may be acting to increase hepatic apoA-I production via this pathway. To address this, HepG2 cells and primary mouse hepatocytes were treated with 200 mM myriocin for up to 48 hours. Myriocin increased apoA-I mRNA and protein levels, by approximately 3-fold and 2-fold, respectively. Myriocin also increased apoA-I secretion up to 3.5-fold, and decreased ERK phosphorylation by approximately 70%. Similar data were obtained when primary hepatocytes were isolated from apoE null mice that were treated with myriocin (intraperitoneal injection at a dose of 0.3 mg / kg body weight). Further experiments revealed that the MAP kinase kinase inhibitor PD98059 potently inhibited ERK phosphorylation, as expected, and increased primary hepatocyte apoA-I production by 3-fold. These data indicate that ERK phosphorylation plays a role in regulating hepatic apoA-I expression, and suggest that the anti-atherogenic mechanism of action for myriocin may be linked to this pathway.

Here is the original:
Myriocin-mediated upregulation of hepatocyte apoA-I synthesis is associated with ERK inhibition

Argent

Tags: , ,

Related posts:

  1. Simultaneous inhibition of TxA2 and PGI2 synthesis increases NO release in mesenteric resistance arteries from cirrhotic rats
  2. The development of hepatic fibrosis occurs normally in AMPK deficient mice
  3. Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy
  4. Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: Role of oxidative stress and PRMT-1
  5. Tetrahydrobiopterin supplementation reduces atherosclerosis and vascular inflammation in Apolipoprotein E-knockout mice

Related posts brought to you by Yet Another Related Posts Plugin.

Advertisement

Leave a Reply